KYMRKymera Therapeutics Inc
KYMR
Kymera Therapeutics Inc849
Mkt Cap
$6.59BVolume
693,609.0052W High
$103.0052W Low
$28.06PE Ratio
-22.60KYMR Fundamentals
Price
$80.71Prev Close
$81.07Open
$81.5150D MA
$84.42Beta
1.61Avg. Volume
510,795.41EPS (Annual)
-$3.69P/B
4.31Rev/Employee
$164,752.10$5,808.19
Poll
Earnings Recap
• Reported GAAP EPS of -$0.71 up 13.41% YoY • Reported revenue of $34.37M up 55.50% YoY • Kymera Therapeutics expects its $1.55 billion cash balance as of March 31, 2026, will provide a cash runway into 2029, supporting multiple clinical inflection points in its pipeline.
Bullish
Kymera Therapeutics achieved a $45 million milestone from Gilead's KT-200 licensing, reported positive KT-621 Phase 1b data, and maintains a strong $1.55 billion cash runway into 2029.
Bearish
Kymera Therapeutics' net loss increased, driven by higher R&D expenses, while key clinical trial data readouts for KT-621 are not expected until mid-to-late 2027.